Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
49 shown of 8,679 total abstracts
  1. Abstract 98792026-04-03 · 21:15 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    H. Rugo, C. Robert, S. Tolaney · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  2. Abstract 101142026-04-02 · 16:00 CT · E450
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-736
    A. Spira, M. Reck, S. Peters, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  3. Abstract 101712026-04-01 · 21:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-532
    F. Andre, C. Saura, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  4. Abstract 97912026-04-04 · 15:45 CT · S100A
    KEYNOTE-839: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Peters, E. Winer, P. Schmid, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  5. Abstract 101642026-04-01 · 14:00 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-332
    M.C. Garassino, H. Borghaei, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  6. Abstract 97712026-04-04 · 19:45 CT · Hall B1
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-100
    R. Herbst, N. Rizvi · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  7. Abstract 104402026-04-01 · 16:15 CT · S100A
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-261
    H. Borghaei, M.C. Garassino, C. Robert, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  8. Abstract 101982026-04-01 · 19:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-880
    C. Saura, T. Mok, H. Rugo, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  9. Abstract 98042026-04-01 · 21:30 CT · E450
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-705
    C. Robert, S. Modi, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  10. Abstract 104072026-04-02 · 20:30 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    G. Curigliano, C. Robert, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  11. Abstract 99902026-04-03 · 21:15 CT · S406
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-620
    S. Tolaney, H. Borghaei, S. Modi · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  12. Abstract 99742026-04-05 · 21:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-523 study)
    E. Winer, C. Saura · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  13. Abstract 104472026-04-01 · 13:30 CT · E450
    KEYNOTE-161: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    H. Rugo, F. Andre, J. Brahmer, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  14. Abstract 102522026-04-03 · 18:45 CT · E450
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    P. Schmid, C. Robert, R. Herbst, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  15. Abstract 100162026-04-01 · 19:00 CT · E450
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-226
    J. Cortes, H. Rugo, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  16. Abstract 98492026-04-04 · 16:15 CT · Arie Crown Theater
    CheckMate-525: Opdivo (nivolumab) adjuvant in metastatic melanoma
    N. Rizvi, J. Brahmer, R. Herbst · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  17. Abstract 99982026-04-05 · 18:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-305
    M.C. Garassino, H. Rugo · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  18. Abstract 104922026-04-05 · 15:45 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-361
    L. Paz-Ares, G. Curigliano, S. Tolaney, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  19. Abstract 99102026-04-05 · 15:45 CT · S406
    CheckMate-435: Opdivo (nivolumab) 1L in metastatic melanoma
    M.C. Garassino, F. Andre, M. Krop, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  20. Abstract 98592026-04-04 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-908
    S. Peters, L. Paz-Ares, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  21. Abstract 99522026-04-03 · 16:30 CT · E450
    CheckMate-979: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    C. Saura, S. Modi, P. Schmid, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  22. Abstract 96672026-04-02 · 13:15 CT · S100A
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-528
    F. Andre, M.C. Garassino, P. Schmid, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  23. Abstract 98162026-04-02 · 14:00 CT · S100A
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-766
    J. Cortes, R. Herbst, H. Borghaei, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  24. Abstract 95532026-04-04 · 16:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-716 study)
    C. Robert, S. Modi, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  25. Abstract 96302026-04-03 · 14:15 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-353
    C. Saura, M. Reck, N. Rizvi, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  26. Abstract 104912026-04-01 · 20:15 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-266
    G. Curigliano, C. Saura · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  27. Abstract 104942026-04-03 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-444 study)
    J. Cortes, S. Tolaney · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  28. Abstract 95972026-04-01 · 18:30 CT · S406
    KEYNOTE-297: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    F. Andre, S. Peters, R. Herbst · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  29. Abstract 100662026-04-03 · 20:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-4 study)
    S. Antonia, S. Tolaney, G. Curigliano, et al. · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  30. Abstract 95312026-04-01 · 20:00 CT · Hall B1
    KEYNOTE-816: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    H. Rugo, C. Robert · University of Chicago
    Poster SessionMelanoma📄🖼️
  31. Abstract 100862026-04-01 · 18:00 CT · Hall B1
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-654
    F. Andre, M. Reck · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  32. Abstract 102202026-04-02 · 19:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-408 study)
    S. Antonia, L. Paz-Ares, A. Spira, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  33. Abstract 97172026-04-04 · 16:30 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-324 study)
    G. Curigliano, J. Cortes, S. Peters, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  34. Abstract 104012026-04-02 · 18:45 CT · S406
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-871
    E. Winer, J. Brahmer, S. Modi, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  35. Abstract 100862026-04-02 · 13:00 CT · S100A
    CheckMate-604: Opdivo (nivolumab) maintenance in metastatic melanoma
    L. Paz-Ares, G. Curigliano, H. Borghaei · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  36. Abstract 97642026-04-05 · 13:45 CT · S406
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-142
    E. Winer, S. Tolaney, T. Mok, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  37. Abstract 95892026-04-02 · 16:15 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-329
    M. Krop, A. Spira, C. Saura, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  38. Abstract 100082026-04-05 · 18:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-851
    J. Cortes, R. Herbst, M.C. Garassino, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  39. Abstract 95982026-04-04 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-948 study)
    L. Paz-Ares, H. Borghaei, C. Robert, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  40. Abstract 100112026-04-02 · 16:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-941
    A. Spira, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  41. Abstract 95952026-04-03 · 14:00 CT · Arie Crown Theater
    KEYNOTE-188: Keytruda (pembrolizumab) 2L in metastatic melanoma
    H. Borghaei, L. Paz-Ares, A. Spira, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  42. Abstract 95852026-04-03 · 21:15 CT · S100A
    KEYNOTE-741: Keytruda (pembrolizumab) 2L in metastatic melanoma
    H. Rugo, C. Robert, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  43. Abstract 99482026-04-05 · 21:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-351
    S. Modi, H. Borghaei, C. Saura, et al. · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  44. Abstract 100672026-04-03 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-324 study)
    M. Krop, S. Tolaney · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  45. Abstract 102632026-04-02 · 13:00 CT · S100A
    KEYNOTE-375: Keytruda (pembrolizumab) 1L in metastatic melanoma
    M. Reck, J. Cortes, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  46. Abstract 99602026-04-04 · 14:15 CT · S100A
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-268
    H. Borghaei, M. Krop, S. Modi · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  47. Abstract 101212026-04-01 · 19:30 CT · Hall B1
    KEYNOTE-474: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    A. Spira, H. Borghaei, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  48. Abstract 99132026-04-03 · 19:00 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-385
    S. Modi, C. Robert, M.C. Garassino, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  49. Abstract 96212026-04-03 · 20:45 CT · Arie Crown Theater
    KEYNOTE-469: Keytruda (pembrolizumab) 1L in metastatic melanoma
    J. Brahmer, M. Reck, N. Rizvi · Karolinska Institute
    Poster SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.